ArticleJournal of gastrointestinal & digestive system2013
Mucins in Gastric Cancer - An Update.
Article in Journal of gastrointestinal & digestive system, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 66 citations in OpenAlex.
- CAR-T cell therapy targeting MUC17 in gastric tumors.Journal for immunotherapy of cancer · 2025Article
- The Role of MUC1 in Gastric Cancer Development.Cancers · 2025Review
- Innovative Immunotherapy and Its Transformative Impact on Gastric Adenocarcinoma: A Comprehensive Review of the Disease's Origins, Epidemiology, Classification, Diagnosis, and Treatment Options.ACS pharmacology & translational science · 2025Review
- The microbiome of pseudomyxoma peritonei: a scoping review.Pleura and peritoneum · 2025Review
- Foreign Mucins Alter the Properties of Reconstituted Gastric Mucus.Biomacromolecules · 2025Article
- Theranostic Approaches for Gastric Cancer: An Overview of In Vitro and In Vivo Investigations.Cancers · 2024Review
- Gastric Cancer: An Up-to-Date Review with New Insights into Early-Onset Gastric Cancer.Cancers · 2024Review
- A microwell platform for high-throughput longitudinal phenotyping and selective retrieval of organoids.Cell systems · 2023Article
- Article
- Shared features of metaplasia and the development of adenocarcinoma in the stomach and esophagus.Frontiers in cell and developmental biology · 2023Article
- Article
- Clinicopathologic and genomic characteristics of mucinous gastric adenocarcinoma.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2022Article
- Mucosal microbiome associates with progression to gastric cancer.Theranostics · 2022Article
- ASF1b is a novel prognostic predictor associated with cell cycle signaling pathway in gastric cancer.Journal of Cancer · 2022Article
- A Fast Alternative to Soft Lithography for the Fabrication of Organ-on-a-Chip Elastomeric-Based Devices and Microactuators.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021Article
- GWAS of peptic ulcer disease implicates Helicobacter pylori infection, other gastrointestinal disorders and depression.Nature communications · 2021Article
- Polymorphism ofFrontiers in oncology · 2021Article
- Gastric Cancer: Epidemiology, Risk Factors, Classification, Genomic Characteristics and Treatment Strategies.International journal of molecular sciences · 2020Review
- Genome-Wide Characterization of RNA Editing Sites in Primary Gastric Adenocarcinoma through RNA-seq Data Analysis.International journal of genomics · 2020Article
- Mucins and their receptors in chronic lung disease.Clinical & translational immunology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Mucins are high-molecular-weight glycoproteins expressed throughout the gastrointestinal tract, with a key role in mucosal protection and function. In gastric cancer expression of MUC5AC and MUC1 is reduced and denovo expression of MUC2 occurs. With progressive loss of tumor differentiation and increased tumor stage, expression of MUC5AC and MUC1 is further reduced, and MUC2 decreases. Isolated MUC2 expression (the intestinal phenotype) correlates with metastatic spread and poor survival. There is emerging evidence that MUC1 acts as an oncoprotein when overexpressed. The cytoplasmic tail of MUC1 interacts with the H. pylori virulence factor cagA and is a major effector of the wnt-β catenin intracellular signalling cascade. Polymorphism in the MUC1 gene has been identified in gastric cancer patients and may have a prospective role in the stratification of high-risk subjects. The MUC1 gene also mediates resistance to the recombinant HER2/neu antibody trastuzumab. Future research efforts will examine targeting MUC1 for therapeutic purposes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.